| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/06/2001 | US6197750 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 03/06/2001 | US6197746 Method of using secretin for treating autism |
| 03/06/2001 | US6197581 Human adenylate cyclase and use therefor |
| 03/06/2001 | US6197339 Dihydro-5-methylamino-4h-imidazo(4,5-ij)quinoline-2(1h)one butenedioate with starches and hydroxypropyl cellulose |
| 03/06/2001 | US6197329 Anti-nausea compositions and methods |
| 03/06/2001 | US6197323 Medicinal preparation containing a lipophilic inert gas |
| 03/06/2001 | US6197300 ftsZ |
| 03/06/2001 | US6197294 Cells containing recombinant polynucleotides coding for cell surface molecules that, when expressed in the cell, result in rejection of the cell by host cell by host immune system; useful for gene therapy |
| 03/06/2001 | US6197069 Adrenomedullin receptor polynucleotides |
| 03/06/2001 | CA2010635C Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| 03/01/2001 | WO2001014570A1 Activatable recombinant neurotoxins |
| 03/01/2001 | WO2001014564A2 Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby |
| 03/01/2001 | WO2001014557A1 Pd-1, a receptor for b7-4, and uses therefor |
| 03/01/2001 | WO2001014554A1 G protein-coupled receptor expressed in brain |
| 03/01/2001 | WO2001014549A1 Gas1 polypeptides |
| 03/01/2001 | WO2001014548A2 New g-protein coupled receptor and dna sequences thereof |
| 03/01/2001 | WO2001014424A2 Human ctla-4 antibodies and their uses |
| 03/01/2001 | WO2001014418A2 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF |
| 03/01/2001 | WO2001014415A2 Egfh2 genes and gene products |
| 03/01/2001 | WO2001014414A2 Human abc2 transporter and uses thereof |
| 03/01/2001 | WO2001014385A1 Dihydrobenzofuran derivatives, process for the preparation thereof and agents |
| 03/01/2001 | WO2001014384A1 Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents |
| 03/01/2001 | WO2001014383A1 Remedies for neuropathic pain and model animals of neuropathic pain |
| 03/01/2001 | WO2001014382A1 Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan |
| 03/01/2001 | WO2001014381A1 Ether derivatives of pyrrolo[1,2-a]quinoxalines, method for producing them and their use in therapy |
| 03/01/2001 | WO2001014380A1 Isomeric fused pyrrolocarbazoles and isoindolones |
| 03/01/2001 | WO2001014377A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 03/01/2001 | WO2001014376A1 Novel spiro compounds |
| 03/01/2001 | WO2001014372A2 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent |
| 03/01/2001 | WO2001014371A1 N-heterocyclic derivatives as nos inhibitors |
| 03/01/2001 | WO2001014353A1 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents |
| 03/01/2001 | WO2001014347A1 Benzoxazine and benzothiazine derivatives and the use thereof in medicaments |
| 03/01/2001 | WO2001014333A1 Substituted piperidine compounds useful as modulators of chemokine receptor activity |
| 03/01/2001 | WO2001014332A1 Piperidine alcohols |
| 03/01/2001 | WO2001014330A2 Phenylpiperazines as serotonin reuptake inhibitors |
| 03/01/2001 | WO2001014320A1 Compounds that inhibit tryptase activity |
| 03/01/2001 | WO2001014316A1 Substituted chiral allosteric hemoglobin modifiers |
| 03/01/2001 | WO2001013957A2 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 03/01/2001 | WO2001013950A1 Percutaneous absorption agents |
| 03/01/2001 | WO2001013945A1 Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis |
| 03/01/2001 | WO2001013938A1 Medicinal composition for percutaneous/permucosal absorption |
| 03/01/2001 | WO2001013936A1 Induced regeneration and repair of damaged neurons and nerve axon myelin |
| 03/01/2001 | WO2001013917A1 Npy antagonists: spiroisoquinolinone derivatives |
| 03/01/2001 | WO2001013916A1 Drugs inhibiting cell death |
| 03/01/2001 | WO2001013911A1 Agents inhibiting hypertensive arteriolar disorder |
| 03/01/2001 | WO2001013909A2 Compositions and methods for treating opiate intolerance |
| 03/01/2001 | WO2001013905A2 Methods for the treatment of mental and vascular disorders |
| 03/01/2001 | WO2001013904A2 Composition comprising a tramadol material and an anticonvulsant drug |
| 03/01/2001 | WO2001013903A2 Treatment of restless leg syndrome with a combination of clonidine and opioid |
| 03/01/2001 | WO2001013902A2 Combination of active agents, said combination containing clonidine and pramipexol |
| 03/01/2001 | WO2001013901A2 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress |
| 03/01/2001 | WO2001013897A1 Oral liquid compositions |
| 03/01/2001 | WO2001013895A2 Controlled-release sedative-hypnotic compositions and methods related thereto |
| 03/01/2001 | WO2001000617A3 Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same |
| 03/01/2001 | WO2001000181A3 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 03/01/2001 | WO2000078948A3 Cloning, expression and characterisation of a cdna coding for a rat brain gamma-hydroxybutyrate (ghb) receptor |
| 03/01/2001 | WO2000075365A3 COMPOUNDS AND METHODS TO ENHANCE rAAV TRANSDUCTION |
| 03/01/2001 | WO2000073449B1 Dna encoding snorf33 receptor |
| 03/01/2001 | WO2000064422A3 Novel treatment of neurotraumatic conditions with raf inhibitor |
| 03/01/2001 | WO2000062786A3 Compositions containing rubidium and in particular rubidium chloride as an antimanic agent and stabilizer for mood swings |
| 03/01/2001 | WO2000046203A3 G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
| 03/01/2001 | DE19941115A1 Neue Benzoxazin- und Bezothiazin-Derivate und deren Verwendung in Arzneimitteln New benzoxazine and Bezothiazin derivatives and their use in medicaments |
| 03/01/2001 | DE19940740A1 Pharmazeutische Salze Pharmaceutical Salts |
| 03/01/2001 | DE19939910A1 Neue Verbindungen, die Tryptase-Aktivität hemmen Novel compounds that inhibit tryptase activity |
| 03/01/2001 | DE10036854A1 Neue kristalline Form von 6-Hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophenhydrochlorid New crystalline form of 6-hydroxy-3- (4- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride |
| 03/01/2001 | CA2589418A1 Human ctla-4 antibodies and their uses |
| 03/01/2001 | CA2384511A1 Substituted chiral allosteric hemoglobin modifiers |
| 03/01/2001 | CA2383456A1 Pd-1, a receptor for b7-4, and uses therefor |
| 03/01/2001 | CA2383371A1 P193 proteins and nucleic acids, and uses thereof |
| 03/01/2001 | CA2383063A1 Human abc2 transporter and uses thereof |
| 03/01/2001 | CA2383057A1 Induced regeneration and repair of damaged neurons and nerve axon myelin |
| 03/01/2001 | CA2382674A1 Gas1 polypeptides |
| 03/01/2001 | CA2382648A1 Drug treatment for restless leg syndrome |
| 03/01/2001 | CA2382418A1 Dihydrobenzofuran derivatives, process for preparing thereof and agents |
| 03/01/2001 | CA2382413A1 Tricyclic dihydrobenzofuran derivatives, process for preparing thereof and agent |
| 03/01/2001 | CA2382295A1 Piperidine alcohols |
| 03/01/2001 | CA2382183A1 New g-protein coupled receptor and dna sequences thereof |
| 03/01/2001 | CA2382123A1 Novel polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby |
| 03/01/2001 | CA2381468A1 Percutaneous absorption preparations containing melatonin receptor agonist for percutaneous treatment of sleep disorders |
| 03/01/2001 | CA2381425A1 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 03/01/2001 | CA2381111A1 Npy antagonists: spiroisoquinolinone derivatives |
| 03/01/2001 | CA2381096A1 Compounds that inhibit tryptase activity |
| 03/01/2001 | CA2380524A1 Compositions and methods for treating opiate intolerance |
| 03/01/2001 | CA2380513A1 Methods for treatment of mental disorders |
| 03/01/2001 | CA2380457A1 Activatable recombinant neurotoxins |
| 03/01/2001 | CA2376606A1 Active substance combination with clonidine |
| 03/01/2001 | CA2376406A1 G protein-coupled receptor expressed in brain |
| 03/01/2001 | CA2376180A1 Oral liquid compositions |
| 02/28/2001 | EP1078928A1 Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 02/28/2001 | EP1078925A1 4-Phenylpiperidine compounds |
| 02/28/2001 | EP1078637A2 Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug |
| 02/28/2001 | EP1078634A1 Medicament for inhibiting NF-kB |
| 02/28/2001 | EP1078633A2 Compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
| 02/28/2001 | EP1078630A1 Use of sigma receptor agonists for the treatment of depression |
| 02/28/2001 | EP1078005A1 Methods for amyloid removal using anti-amyloid antibodies |
| 02/28/2001 | EP1077994A1 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same |
| 02/28/2001 | EP1077985A1 Process for preparation of 4,5-epoxymorphinan-6-oxyglucuronides |
| 02/28/2001 | EP1077978A1 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 02/28/2001 | EP1077974A1 Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 02/28/2001 | EP1077973A2 Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient |